Global Biosimilar Market Trends
The global biosimilar market has grown to approximately $65 billion as of 2025 and is projected to reach $120 billion by 2030. As the patent cliff — the accelerating expiration of originator biologic patents — continues, biosimilar adoption rates are rising rapidly in developed markets including the United States, Europe, and Japan.
Amid these global trends, Bangladesh is attracting attention as the "second biosimilar production hub" after India. Low production costs, TRIPs exemption (until 2032), a young scientific workforce, and a strong export ambition are Bangladesh's core competitive factors. In particular, rising production costs and tightening regulations in India are generating a spillover benefit for Bangladesh.
Bangladesh's Competitive Positioning
Comparing Bangladesh's competitiveness as a global biosimilar production hub against India, China, and Korea reveals that Bangladesh demonstrates strength in a "cost leadership" position, and a strategy targeting emerging markets and the UN procurement market — rather than entry into regulated markets (US, EU) — is the most realistic approach.
| Factor | Bangladesh | India | China | Korea |
|---|---|---|---|---|
| Production Cost | Lowest | Low | Medium | High |
| Technology Level | Lower-medium | Upper-medium | Upper-medium | Best-in-class |
| Regulatory Capability | Growing | High | High | Best-in-class |
| TRIPs Exemption | Until 2032 | None | None | None |
| WHO PQ | 3 in progress | 60+ | 20+ | 10+ |
| Target Market | Emerging/UN | Global | EU/US | EU/US |
| Monthly Labor Cost | $200–400 | $500–800 | $700–1,200 | $2,500+ |
Biosimilar Export Hub Potential
Three conditions are required for Bangladesh to emerge as a biosimilar export hub. First, entry into the UN procurement market through WHO PQ certification; second, the establishment of a bio API park to improve active pharmaceutical ingredient self-sufficiency; and third, capability enhancement through technology partnerships with global partners.
Detailed Comparative Analysis with India
India is the most powerful emerging biosimilar producer in the global market. However, rising production costs in India, tightening regulations (CDSCO), and increasing intellectual property protection trends are creating opportunities for Bangladesh. The following presents a detailed comparison of the two countries' biosimilar industries.
| Factor | Bangladesh | India |
|---|---|---|
| Biosimilar Market | $350M | $5.5B |
| WHO PQ Held | 0 (3 in progress) | 25+ |
| Number of Bio Companies | 12 | 200+ |
| mAb Producing Companies | 3 | 30+ |
| API Self-Sufficiency | 30% | 80% |
| Average Monthly Labor Cost | $300 | $700 |
| TRIPs Exemption | Until 2032 | None (TRIPS compliant) |
| Regulatory Level | NRA Level 2 | NRA Level 3+ |
Bangladesh currently occupies the position of "high-potential late mover" in the global biosimilar market. The core challenge is to maximize the time-limited advantage of the TRIPs exemption while rapidly elevating technical capabilities and regulatory standards. In this process, strategic partnerships with Korean bio companies can be a win-win for both sides.